Data / Research funding / Cancer Genomics
Cancer Genomics: 3,570 NIH awards ($4.3B) to 368 organizations
3,570 NIH awards ($4.3B) in the NIH spending category Cancer Genomics, to 368 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 3,570 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $41,720,565 | June 1, 1997 | November 30, 2025 | FERRIS, ROBERT L. | reporter.nih.gov |
| University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $34,050,628 | December 1, 1996 | November 30, 2026 | LERMAN, CARYN | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,048,179 | July 4, 1997 | June 30, 2030 | RUSTGI, ANIL K | reporter.nih.gov |
| Childhood Cancer Survivorship Study | NIH | National Cancer Institute | 2021 to 2025 | $27,522,831 | July 20, 1993 | November 30, 2026 | ARMSTRONG, GREGORY | reporter.nih.gov |
| TO PROVIDE SEQUENCING SERVICES USING WHOLE GENOME SEQUENCING (GERMLINE FFPE) FOR NCI (KLEIN) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $24,069,896 | September 27, 2023 | December 31, 2025 | DOHENY, KIM | reporter.nih.gov |
| SF Bay Area MACS/WIHS Combined Cohort Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $23,128,905 | April 1, 2019 | September 30, 2026 | TIEN, PHYLLIS C | reporter.nih.gov |
| Administrative Supplement to Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $21,104,098 | September 1, 2025 | August 31, 2026 | BOUTROS, PAUL CHRISTOPHER | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $20,980,807 | December 1, 1996 | February 28, 2029 | MAITRA, ANIRBAN | reporter.nih.gov |
| Nebraska Research Network in Functional Genomics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,833,603 | September 30, 2001 | April 30, 2026 | SORGEN, PAUL L | reporter.nih.gov |
| Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $19,790,656 | April 10, 2019 | September 30, 2026 | WOLINSKY, STEVEN M | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,528,719 | June 1, 1997 | June 30, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| The Wake Forest Nonhuman Primate Radiation Survivor Cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,517,826 | August 1, 2020 | July 31, 2027 | CLINE, J. MARK | reporter.nih.gov |
| The American Lung Association (ALA) Lung Health Cohort | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $17,159,433 | June 15, 2019 | June 30, 2026 | KALHAN, RAVI | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $16,870,049 | August 4, 1997 | November 30, 2029 | DRAGNEV, KONSTANTIN H. | reporter.nih.gov |
| Understanding Population Differences in Cancer: The MEC Study | NIH | National Cancer Institute | 2021 to 2025 | $15,674,930 | September 1, 2012 | August 31, 2027 | LE MARCHAND, LOIC | reporter.nih.gov |
| Life Course Cancer Epidemiology Cohort in Women | NIH | National Cancer Institute | 2021 to 2025 | $15,280,631 | June 1, 2013 | August 31, 2028 | ELIASSEN, A. HEATHER | reporter.nih.gov |
| The Alliance NCTN Biorepository and Biospecimen Resource | NIH | National Cancer Institute | 2021 to 2025 | $15,002,332 | May 19, 2015 | March 31, 2027 | WATSON, MARK A. | reporter.nih.gov |
| The UCSC Genome Browser | NIH | National Human Genome Research Institute | 2022 to 2025 | $14,584,394 | July 12, 2001 | April 30, 2027 | HAEUSSLER, MAXIMILIAN | reporter.nih.gov |
| Children's Oncology Group Pediatric Early Phase Clinical Trial Network | NIH | National Cancer Institute | 2021 to 2024 | $14,041,303 | May 3, 2024 | July 31, 2024 | WEIGEL, BRENDA J. | reporter.nih.gov |
| Center for Live Cell Genomics | NIH | National Human Genome Research Institute | 2021 to 2025 | $11,992,289 | September 15, 2021 | June 30, 2027 | HAUSSLER, DAVID H | reporter.nih.gov |
| Cancer Center Support (CORE) Grant | NIH | National Cancer Institute | 2021 to 2025 | $11,628,123 | August 1, 1997 | June 30, 2030 | PALUCKA, ANNA KAROLINA | reporter.nih.gov |
| Characterizing pediatric genomes through an optimized sequencing approach | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $11,335,114 | September 23, 2016 | August 31, 2025 | GRIMWOOD, JANE | reporter.nih.gov |
| SPORE in Brain Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,413,880 | September 1, 2008 | August 31, 2029 | LANG, FREDERICK F | reporter.nih.gov |
| MSK SPORE in Genomic Instability in Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,402,609 | August 13, 2020 | July 31, 2026 | POWELL, SIMON N. | reporter.nih.gov |
| Determining the mechanism of pks+ E.coli-associated carcinogenesis in early onset colorectal cancer. | NIH | National Cancer Institute | 2022 to 2025 | $9,558,240 | September 20, 2022 | August 31, 2027 | O'REILLY, EILEEN MARY | reporter.nih.gov |
| Statistical Methods for Integrative Genomics in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $8,721,062 | July 1, 2016 | August 31, 2027 | GAUDERMAN, WILLIAM JAMES | reporter.nih.gov |
| Stanford Tissue Mapping Center | NIH | National Human Genome Research Institute | 2022 to 2025 | $7,785,758 | September 23, 2022 | June 30, 2026 | SNYDER, MICHAEL P. | reporter.nih.gov |
| Understanding adenoma progression: Interplay among tissue microenvironment, clonal architecture, and gut microbiome | NIH | National Cancer Institute | 2022 to 2025 | $7,696,898 | September 20, 2022 | August 31, 2027 | GRADY, WILLIAM MALLORY | reporter.nih.gov |
| PharmGKB | NIH | National Human Genome Research Institute | 2021 to 2025 | $6,940,000 | April 3, 2020 | December 31, 2026 | KLEIN, TERI ELLEN | reporter.nih.gov |
| The Global Alliance for Genomics and Health: Setting the Standards for Genomics and Health-Related Data Sharing | NIH | National Human Genome Research Institute | 2021 to 2025 | $6,892,586 | February 5, 2021 | January 31, 2027 | REHM, HEIDI L | reporter.nih.gov |
| The 10,000 Families Cohort: a new study to understand the environmental causes of cancer | NIH | National Cancer Institute | 2023 to 2025 | $6,827,634 | September 24, 2021 | August 31, 2028 | POYNTER, JENNY N. | reporter.nih.gov |
| PROMINENT - UCSF | NIH | National Cancer Institute | 2022 to 2025 | $6,721,823 | June 22, 2022 | May 31, 2026 | BALMAIN, ALLAN | reporter.nih.gov |
| Washington University/Siteman Cancer Center Lead Academic Site | NIH | National Cancer Institute | 2021 to 2025 | $6,572,668 | March 5, 2019 | February 28, 2026 | BARTLETT, NANCY L | reporter.nih.gov |
| Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication | NIH | National Cancer Institute | 2022 to 2025 | $6,547,653 | September 1, 2025 | August 31, 2027 | TANG, LI | reporter.nih.gov |
| CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan | NIH | National Cancer Institute | 2023 to 2025 | $6,381,605 | September 22, 2021 | August 31, 2027 | FRIEDMAN, DEBRA L. | reporter.nih.gov |
| Synergistic role of signaling and epigenetics in leukemic transformation | NIH | National Cancer Institute | 2021 to 2025 | $6,322,598 | January 17, 2017 | July 31, 2030 | LEVINE, ROSS L | reporter.nih.gov |
| Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies | NIH | National Cancer Institute | 2022 to 2025 | $6,280,793 | September 14, 2022 | July 31, 2027 | CHAN, TIMOTHY AN-THY | reporter.nih.gov |
| Translating genomic discoveries to improved outcomes for high risk acute leukemia | NIH | National Cancer Institute | 2021 to 2025 | $6,239,168 | January 19, 2017 | August 31, 2030 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| The cBioPortal for Cancer Genomics | NIH | National Cancer Institute | 2022 to 2025 | $5,919,979 | September 5, 2022 | August 31, 2027 | SCHULTZ, NIKOLAUS | reporter.nih.gov |
| High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials | NIH | National Cancer Institute | 2023 to 2025 | $5,867,691 | September 30, 2017 | June 30, 2028 | GNJATIC, SACHA | reporter.nih.gov |
| Cancer Immune Monitoring and Analysis Center | NIH | National Cancer Institute | 2023 to 2025 | $5,746,876 | September 30, 2017 | June 30, 2028 | WU, CATHERINE JU-YING | reporter.nih.gov |
| MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC | NIH | National Cancer Institute | 2023 to 2025 | $5,677,452 | September 30, 2017 | June 30, 2028 | HAYMAKER, CARA L | reporter.nih.gov |
| Mutographs differentiating the inheritance and temporal onset of multiple myeloma | NIH | National Cancer Institute | 2021 to 2025 | $5,575,548 | August 11, 2021 | July 31, 2026 | MORGAN, GARETH JOHN | reporter.nih.gov |
| The role of stem cells and the microenvironment in gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $5,569,272 | January 7, 2016 | August 31, 2030 | WANG, TIMOTHY CRAGIN | reporter.nih.gov |
| Myeloma multidimensional precancer atlas | NIH | National Cancer Institute | 2024 to 2025 | $5,566,942 | September 18, 2024 | August 31, 2029 | GHOBRIAL, IRENE M. | reporter.nih.gov |
| Stanford Cancer Immune Monitoring and Analysis Center (CIMAC) | NIH | National Cancer Institute | 2023 to 2025 | $5,504,598 | September 30, 2017 | June 30, 2028 | MAECKER, HOLDEN T. | reporter.nih.gov |
| Proteogenomic Characterization of Tumor Tissues and Preclinical Models with High Precision | NIH | National Cancer Institute | 2022 to 2025 | $5,481,323 | June 1, 2022 | May 31, 2027 | ZHANG, HUI | reporter.nih.gov |
| Effects of Intermittent Energy Restriction on Intra-Abdominal Fat and the Gut Microbiome: A Randomized Trial | NIH | National Cancer Institute | 2021 to 2025 | $5,478,236 | September 22, 2021 | August 31, 2026 | LE MARCHAND, LOIC | reporter.nih.gov |
| Washington University PDX Development and Trial Center | NIH | National Cancer Institute | 2021 to 2025 | $5,436,401 | September 30, 2017 | July 31, 2028 | DING, LI | reporter.nih.gov |
| Center for Advanced Multi-Omic Characterization of Cancer | NIH | National Cancer Institute | 2022 to 2025 | $5,390,170 | June 1, 2022 | May 31, 2027 | LIU, TAO | reporter.nih.gov |
| CYTOSCAPE: AN ECOSYSTEM FOR NETWORK GENOMICS | NIH | National Human Genome Research Institute | 2022 to 2025 | $5,378,912 | September 1, 2022 | June 30, 2027 | IDEKER, TREY | reporter.nih.gov |
| eDyNAmiC - STANFORD | NIH | National Cancer Institute | 2022 to 2025 | $5,333,113 | June 1, 2025 | May 31, 2026 | MISCHEL, PAUL S | reporter.nih.gov |
| Cell plasticity in the origin of gastric carcinogenesis | NIH | National Cancer Institute | 2022 to 2025 | $5,262,457 | September 1, 2025 | August 31, 2027 | CHOI, EUNYOUNG | reporter.nih.gov |
| Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery | NIH | National Cancer Institute | 2021 to 2025 | $5,246,301 | August 1, 2015 | July 31, 2028 | MEYERSON, MATTHEW L. | reporter.nih.gov |
| Pre-cancer atlas of skin cancer | NIH | National Cancer Institute | 2024 to 2025 | $5,182,743 | September 1, 2024 | August 31, 2029 | SHAIN, ALAN HUNTER | reporter.nih.gov |
| Genomic and Genomic Variation in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $5,164,514 | January 7, 2022 | April 30, 2027 | REBBECK, TIMOTHY RICHARD | reporter.nih.gov |
| Human Prostate Tumor Atlas Center | NIH | National Cancer Institute | 2024 to 2025 | $5,162,603 | September 1, 2024 | August 31, 2029 | DING, LI | reporter.nih.gov |
| A Multimodal 3D Atlas of Colorectal Cancer Across Ages of Onset | NIH | National Cancer Institute | 2024 to 2025 | $5,159,940 | September 1, 2024 | August 31, 2029 | LAU, KEN S | reporter.nih.gov |
| Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA) | NIH | National Cancer Institute | 2024 to 2025 | $5,130,804 | September 1, 2024 | August 31, 2029 | FAN, RONG | reporter.nih.gov |
| The stromal microenvironment as a co-organizer of bladder carcinogenesis and progression | NIH | National Cancer Institute | 2023 to 2025 | $5,126,849 | September 22, 2022 | August 31, 2027 | CHAN, KEITH SYSON | reporter.nih.gov |
| Precision microRNA medicine in cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,120,362 | August 22, 2019 | July 31, 2026 | SLACK, FRANK J. | reporter.nih.gov |
| Comprehensive Cancer Center Program at Fox Chase | NIH | National Cancer Institute | 2021 to 2025 | $5,119,493 | July 1, 1997 | April 30, 2030 | WIEST, DAVID L. | reporter.nih.gov |
| Precision approaches to refining TP53-associated cancer risk | NIH | National Cancer Institute | 2021 to 2023 | $5,115,949 | September 18, 2019 | August 31, 2025 | GRUBER, STEPHEN B | reporter.nih.gov |
| Tracking the evolution of breast cancer through single cell analyses of premalignant breast tissues from women at high risk for cancer development | NIH | National Cancer Institute | 2021 to 2025 | $5,046,546 | September 1, 2019 | August 31, 2026 | BRUGGE, JOAN SIEFERT | reporter.nih.gov |
| Molecular Mechanism of Mammalian DNA Excision Repair and the Circadian Clock | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,040,955 | April 1, 2016 | August 31, 2027 | SANCAR, AZIZ | reporter.nih.gov |
| Differential function and tumor vulnerabilities revealed by RAS membrane trafficking | NIH | National Cancer Institute | 2021 to 2025 | $4,958,727 | September 1, 2020 | August 31, 2027 | PHILIPS, MARK REID | reporter.nih.gov |
| Gastroesophageal junction stem cells as the origin of Barretts esophagus and cancer | NIH | National Cancer Institute | 2022 to 2025 | $4,948,268 | September 1, 2025 | August 31, 2027 | WANG, TIMOTHY CRAGIN | reporter.nih.gov |
| Targeting the MYC Pathway for the Treatment of Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,931,456 | September 8, 2020 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Leveraging Prospective Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores | NIH | National Cancer Institute | 2021 to 2025 | $4,909,720 | June 16, 2021 | May 31, 2027 | CHEN, FEI | reporter.nih.gov |
| The St. Jude Lifetime Cohort | NIH | National Cancer Institute | 2021 to 2024 | $4,907,509 | July 9, 2015 | June 30, 2025 | HUDSON, MELISSA M | reporter.nih.gov |
| Genome instability in cancer: telomeres and DNA repair | NIH | National Cancer Institute | 2021 to 2025 | $4,866,062 | September 2, 2016 | August 31, 2030 | DE LANGE, TITIA | reporter.nih.gov |
| Making cancer precision medicine real: bottlenecks and opportunities | NIH | National Cancer Institute | 2021 to 2025 | $4,848,173 | September 16, 2019 | August 31, 2026 | GOLUB, TODD R. | reporter.nih.gov |
| Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level | NIH | National Cancer Institute | 2021 to 2025 | $4,812,861 | August 14, 2015 | July 31, 2029 | CALIFANO, ANDREA | reporter.nih.gov |
| Mechanisms of regulated translation control in cancer and its therapeutic implications | NIH | National Cancer Institute | 2021 to 2025 | $4,757,711 | August 6, 2019 | July 31, 2027 | RUGGERO, DAVIDE | reporter.nih.gov |
| Post genome wide association studies in testicular germ cell tumors | NIH | National Cancer Institute | 2021 to 2024 | $4,743,103 | September 21, 2012 | August 31, 2025 | NATHANSON, KATHERINE L. | reporter.nih.gov |
| Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $4,722,849 | June 16, 2022 | May 31, 2027 | PAULOVICH, AMANDA G | reporter.nih.gov |
| Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation | NIH | National Cancer Institute | 2021 to 2025 | $4,608,771 | April 1, 2017 | July 31, 2031 | COFFEY, ROBERT J. | reporter.nih.gov |
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $4,603,890 | June 15, 2022 | May 31, 2027 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| Molecular Pathogenesis of Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $4,591,274 | August 13, 2015 | June 30, 2029 | LEY, TIMOTHY J. | reporter.nih.gov |
| Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer Research | NIH | National Cancer Institute | 2021 to 2025 | $4,582,548 | August 5, 2015 | July 31, 2029 | LIN, XIHONG | reporter.nih.gov |
| Comprehensive molecular characterization of endometrial cancer, etiologic heterogeneity, and racial disparities | NIH | National Cancer Institute | 2021 to 2025 | $4,544,010 | February 5, 2021 | January 31, 2027 | DE VIVO, IMMACULATA | reporter.nih.gov |
| Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $4,541,273 | September 17, 2019 | August 31, 2026 | TING, JENNY P | reporter.nih.gov |
| Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health Study | NIH | National Cancer Institute | 2021 to 2023 | $4,508,718 | July 22, 2014 | June 30, 2025 | ELIASSEN, A. HEATHER | reporter.nih.gov |
| Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application | NIH | National Cancer Institute | 2025 | $4,394,441 | August 1, 2025 | July 31, 2029 | FOX, ELIZABETH | reporter.nih.gov |
| The Integrative Genomics Viewer (IGV) for Cancer Research | NIH | National Cancer Institute | 2021 to 2025 | $4,380,809 | September 7, 2021 | August 31, 2027 | MESIROV, JILL P. | reporter.nih.gov |
| ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) | NIH | National Cancer Institute | 2021 to 2025 | $4,374,283 | March 1, 2025 | February 28, 2026 | LEVINE, ROSS L | reporter.nih.gov |
| Genetic Susceptibility and Biomarkers of Platinum-related Toxicities | NIH | National Cancer Institute | 2021 to 2025 | $4,370,186 | September 25, 2012 | June 30, 2027 | TRAVIS, LOIS B. | reporter.nih.gov |
| Genetic and molecular basis for variation in human skin pigmentation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $4,362,884 | May 1, 2020 | April 30, 2026 | MARKS, MICHAEL S | reporter.nih.gov |
| Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk | NIH | National Cancer Institute | 2021 to 2025 | $4,355,861 | January 13, 2021 | December 31, 2026 | GOODE, ELLEN L. | reporter.nih.gov |
| The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,334,400 | September 1, 2016 | August 31, 2031 | RAO, ANJANA | reporter.nih.gov |
| Germline variation in homologous recombination repair genes in Hispanic/Latina women to predict breast cancer risk and response to treatment | NIH | National Institute on Minority Health and Health Disparities | 2025 | $4,307,388 | September 1, 2025 | June 30, 2029 | ZIV, ELAD | reporter.nih.gov |
| NCI'S GENOMIC CHARACTERIZATION CENTER IDIQ | NIH | National Cancer Institute | 2021 to 2024 | $4,299,683 | September 10, 2021 | September 9, 2026 | GABRIEL, STACY | reporter.nih.gov |
| Pediatric Oncology In Vivo Testing Program Coordinating Center | NIH | National Cancer Institute | 2021 to 2025 | $4,288,627 | August 25, 2021 | June 30, 2026 | BULT, CAROL J | reporter.nih.gov |
| Mayo Clinic Center for Clinical Proteomics | NIH | National Cancer Institute | 2022 to 2025 | $4,271,766 | June 1, 2022 | May 31, 2027 | PANDEY, AKHILESH | reporter.nih.gov |
| Rates and mechanisms of age-related somatic mutation in normal and Alzheimer brain | NIH | National Institute on Aging | 2021 to 2025 | $4,268,929 | April 1, 2021 | September 30, 2026 | WALSH, CHRISTOPHER A. | reporter.nih.gov |
| Center of Excellence for High Throughput Proteogenomic Characterization | NIH | National Cancer Institute | 2022 to 2025 | $4,262,276 | June 15, 2022 | May 31, 2027 | CARR, STEVEN A | reporter.nih.gov |
| Leveraging Omics and Electronic Health Records Data to study Colorectal Adenoma genetics and Drug Repurposing | NIH | National Cancer Institute | 2025 | $4,174,595 | September 10, 2025 | August 31, 2029 | GUO, XINGYI | reporter.nih.gov |
| Biomarker-Based Phase IIB Trial of (Bazedoxifene-Conjugated Estrogen) to Reduce Risk for Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,143,666 | February 26, 2021 | July 31, 2027 | FABIAN, CAROL J. | reporter.nih.gov |
| Insights from Asian Populations into Disparities in Breast Cancer Prognosis and Outcomes | NIH | National Cancer Institute | 2021 to 2024 | $4,137,490 | June 8, 2020 | May 31, 2026 | GOMEZ, SCARLETT L | reporter.nih.gov |
| Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | NIH | National Cancer Institute | 2022 to 2025 | $4,096,241 | September 19, 2022 | August 31, 2027 | HAHN, WILLIAM C. | reporter.nih.gov |
| Initiation of Diffuse and Intestinal Non-Cardia Gastric Cancer | NIH | National Cancer Institute | 2022 to 2025 | $4,080,056 | September 1, 2025 | August 31, 2027 | RYEOM, SANDRA | reporter.nih.gov |
| Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,072,882 | September 1, 2017 | July 31, 2028 | GOEL, AJAY | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Mechanisms of chromosome segregation, aneuploidy, and tumorigenesis | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $4,006,479 | May 1, 2017 | August 31, 2027 | CLEVELAND, DON W | reporter.nih.gov |
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | NIH | National Cancer Institute | 2021 to 2025 | $3,984,664 | July 16, 2018 | January 31, 2027 | BICKEL, KELLIE | reporter.nih.gov |
| Characterizing germline and somatic alterations by glioma subtypes and clinical outcome | NIH | National Cancer Institute | 2021 to 2023 | $3,952,018 | May 9, 2019 | April 30, 2026 | BONDY, MELISSA L. | reporter.nih.gov |
| Targeting Epigenetic Circuits in B-Cell Lymphomas | NIH | National Cancer Institute | 2021 to 2024 | $3,926,225 | September 13, 2018 | August 31, 2025 | MELNICK, ARI M. | reporter.nih.gov |
| Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,920,220 | June 13, 2022 | May 31, 2027 | GOVINDAN, RAMASWAMY | reporter.nih.gov |
| Mouse Models of Human Cancer Database | NIH | National Cancer Institute | 2021 to 2025 | $3,918,774 | December 1, 2000 | June 30, 2027 | BULT, CAROL J | reporter.nih.gov |
| Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability | NIH | National Cancer Institute | 2021 to 2024 | $3,915,629 | August 1, 2018 | July 31, 2025 | IACOBUZIO-DONAHUE, CHRISTINE A | reporter.nih.gov |
| Bay Area Cancer Target Discovery and Development | NIH | National Cancer Institute | 2022 to 2025 | $3,880,946 | September 13, 2022 | August 31, 2027 | MCMANUS, MICHAEL T | reporter.nih.gov |
| Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women | NIH | National Cancer Institute | 2021 to 2023 | $3,873,758 | February 1, 2019 | January 31, 2026 | YAO, SONG | reporter.nih.gov |
| Integrating tumor and stroma to understand and predict treatment response | NIH | National Cancer Institute | 2022 to 2025 | $3,846,395 | September 1, 2022 | August 31, 2027 | YEH, JEN JEN | reporter.nih.gov |
| The UCLA Center in Early Detection of Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,825,539 | September 17, 2018 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| HIV Genomic Aging Project in Oncology (HIV-GAP) | NIH | National Cancer Institute | 2021 to 2025 | $3,820,924 | September 20, 2021 | August 31, 2027 | COGHILL, ANNA | reporter.nih.gov |
| Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance | NIH | National Cancer Institute | 2021 to 2024 | $3,811,506 | May 1, 2020 | August 31, 2025 | CHAN, TIMOTHY AN-THY | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| Integrating genomics and the protein interactome for HPV+ head and neck cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $3,779,781 | August 15, 2018 | July 31, 2025 | GRANDIS, JENNIFER RUBIN | reporter.nih.gov |
| Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources | NIH | National Cancer Institute | 2021 to 2025 | $3,765,580 | September 1, 2021 | August 31, 2027 | ZHU, JINGCHUN | reporter.nih.gov |
| Role of ncRNA Surveillance Complex "RNA Exosome" in Class Switch Recombination and Somatic Hypermutation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,761,466 | May 7, 2012 | April 30, 2027 | BASU, UTTIYA | reporter.nih.gov |
| Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,743,381 | September 10, 2021 | August 31, 2027 | ZEBRACK, BRADLEY JAY | reporter.nih.gov |
| Rational Integration of Polygenic Risk Scores (RIPS) | NIH | National Human Genome Research Institute | 2022 to 2025 | $3,737,256 | March 10, 2022 | February 28, 2027 | PETERSON, JOSEPH F. | reporter.nih.gov |
| Ikaros regulation: study on hemo-lymphopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,733,682 | September 5, 2011 | March 31, 2029 | GEORGOPOULOS, KATIA | reporter.nih.gov |
| Proteogenomic translator for cancer biomarker discovery towards precision medicine | NIH | National Cancer Institute | 2022 to 2025 | $3,707,896 | May 1, 2025 | April 30, 2026 | WANG, PEI | reporter.nih.gov |
| Genetic Predictors of Prostate Cancer Survival | NIH | National Cancer Institute | 2021 to 2025 | $3,655,797 | January 15, 2021 | December 31, 2026 | KLEIN, ROBERT J. | reporter.nih.gov |
| Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | NIH | National Cancer Institute | 2021 to 2025 | $3,652,183 | July 1, 2021 | June 30, 2026 | KUNG, ANDREW L | reporter.nih.gov |
| Validation of epigenomic biomarkers for thyroid cancer diagnostics | NIH | National Cancer Institute | 2021 to 2025 | $3,647,565 | June 15, 2021 | November 30, 2026 | HAHN, MARIA | reporter.nih.gov |
| Mechanism of estrogen independent proliferation in ER+ breast cancer cells | NIH | National Cancer Institute | 2021 to 2025 | $3,641,042 | September 1, 2021 | August 31, 2027 | BILD, ANDREA HOPE | reporter.nih.gov |
| In Vivo Testing of Novel Drug Combinations for Pediatric Soft Tissue Sarcomas | NIH | National Cancer Institute | 2021 to 2025 | $3,632,740 | July 1, 2021 | June 30, 2027 | DYER, MICHAEL A | reporter.nih.gov |
| Exploring Precision Oncology: From Gene Fusions to lncRNAs | NIH | National Cancer Institute | 2021 to 2024 | $3,631,025 | September 1, 2018 | August 31, 2025 | CHINNAIYAN, ARUL M | reporter.nih.gov |
| GenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer Research | NIH | National Cancer Institute | 2021 to 2024 | $3,609,857 | June 1, 2020 | May 31, 2025 | MESIROV, JILL P. | reporter.nih.gov |
| Role of the Epitranscriptome in Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,597,010 | August 1, 2019 | November 30, 2024 | GREGORY, RICHARD I. | reporter.nih.gov |
| Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology | NIH | National Cancer Institute | 2021 to 2025 | $3,589,331 | July 1, 2019 | August 31, 2026 | PERMUTH, JENNIFER B | reporter.nih.gov |
| Genetics, Epigenetics, and Risk Prediction for Esophageal Adenocarcinoma | NIH | National Cancer Institute | 2022 to 2025 | $3,588,780 | September 12, 2022 | August 31, 2027 | KOOPERBERG, CHARLES L | reporter.nih.gov |
| Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children | NIH | National Cancer Institute | 2021 to 2025 | $3,570,931 | August 5, 2021 | July 31, 2026 | BURRIDGE, PAUL W. | reporter.nih.gov |
| Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,563,506 | August 7, 2018 | July 31, 2029 | SEN, SUBRATA | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $3,557,045 | May 1, 2021 | April 30, 2024 | NIXON, DOUGLAS F | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program: Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,549,742 | July 1, 2021 | June 30, 2027 | MOSSE, YAEL P | reporter.nih.gov |
| University of California and UT Southwestern D-PDTC | NIH | National Cancer Institute | 2023 to 2025 | $3,532,429 | August 1, 2023 | July 31, 2028 | CARVAJAL CARMONA, LUIS GUILLERMO | reporter.nih.gov |
| Software and algorithms for elucidating the structure, function, and evolution of extrachromosomal DNA | NIH | National Cancer Institute | 2021 to 2025 | $3,494,584 | September 1, 2021 | August 31, 2027 | BAFNA, VINEET | reporter.nih.gov |
| Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $3,480,276 | August 1, 2025 | July 31, 2029 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center | NIH | National Cancer Institute | 2021 to 2025 | $3,465,294 | January 2, 2025 | February 28, 2026 | LEAL, TICIANA | reporter.nih.gov |
| Epi-genetic Programs in Cancer Progression | NIH | National Cancer Institute | 2021 to 2023 | $3,463,200 | September 1, 2017 | August 31, 2024 | WEINBERG, ROBERT A | reporter.nih.gov |
| Genomic Biology of the Tandem Duplicator Phenotype in Mouse and Human Cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,456,605 | December 1, 2020 | November 30, 2025 | LIU, EDISON TAK-BUN | reporter.nih.gov |
| New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,453,304 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| Molecular prediction of myeloma in African Americans | NIH | National Cancer Institute | 2022 to 2025 | $3,450,221 | September 12, 2022 | August 31, 2027 | MARINAC, CATHERINE | reporter.nih.gov |
| Detecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer Prevention | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $3,449,786 | January 22, 2021 | October 31, 2025 | ALEXANDROV, LUDMIL B | reporter.nih.gov |
| Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,448,227 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| Oncogenic mechanisms, molecular stratification and therapeutic targets of brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $3,447,832 | September 24, 2021 | August 31, 2028 | IAVARONE, ANTONIO | reporter.nih.gov |
| TLE transcription cofactors in anti-viral and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,436,588 | July 18, 2025 | June 30, 2029 | XUE, HAI-HUI | reporter.nih.gov |
| Cell Identity Determination in Human Brain: Somatic Mutation and Cell Lineage | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,434,150 | December 16, 1994 | June 30, 2030 | WALSH, CHRISTOPHER A. | reporter.nih.gov |
| Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $3,431,899 | February 1, 2021 | January 31, 2026 | MERAD, MIRIAM | reporter.nih.gov |
| Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | NIH | National Cancer Institute | 2021 to 2025 | $3,409,205 | April 1, 2021 | March 31, 2026 | KADOCH, CIGALL | reporter.nih.gov |
| Identification of Genes and DNA Methylation Markers for Lung Cancer Risk by Integrating Multi-omics Data | NIH | National Cancer Institute | 2021 to 2025 | $3,377,653 | January 22, 2021 | December 31, 2026 | CAI, QIUYIN | reporter.nih.gov |
| B cell determinants of EBV latency (supplement) | NIH | National Cancer Institute | 2022 to 2025 | $3,376,443 | September 9, 2022 | August 31, 2027 | CESARMAN, ETHEL | reporter.nih.gov |
| UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center | NIH | National Cancer Institute | 2021 to 2025 | $3,358,438 | March 13, 2019 | February 28, 2026 | MERKER, JASON DEREK | reporter.nih.gov |
| DNA Methylation Markers, Genes and Breast Cancer Risk | NIH | National Cancer Institute | 2021 to 2025 | $3,357,930 | April 1, 2021 | March 31, 2027 | LONG, JIRONG | reporter.nih.gov |
| Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | NIH | National Cancer Institute | 2021 to 2025 | $3,352,278 | March 2, 2021 | February 28, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | NIH | National Cancer Institute | 2022 to 2025 | $3,342,109 | September 1, 2022 | August 31, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,333,223 | January 1, 2021 | December 31, 2026 | KELSEY, KARL TIMOTHY | reporter.nih.gov |
| Individual and social contextual factors in relation to DNA methylation, biological aging, and lung cancer risk | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,331,422 | August 24, 2021 | April 30, 2027 | CAI, QIUYIN | reporter.nih.gov |
| Cancer Immune-Interception for Lynch Syndrome | NIH | National Cancer Institute | 2021 to 2025 | $3,326,163 | September 21, 2021 | August 31, 2026 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Investigating the role of TET deficiency in promoting T cell expansion and inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,325,237 | June 7, 2017 | May 31, 2027 | RAO, ANJANA | reporter.nih.gov |
| Epigenetic study of oral HPV infection-associated oral cancer in people living with HIV in Nigeria | NIH | National Cancer Institute | 2022 to 2025 | $3,301,620 | September 16, 2022 | August 31, 2027 | HOU, LIFANG | reporter.nih.gov |
| Impact of HIV, oral microbiome and mycobiome on oral HPV persistence | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,289,768 | September 1, 2022 | August 31, 2027 | BURK, ROBERT D | reporter.nih.gov |
| Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy | NIH | National Cancer Institute | 2021 to 2024 | $3,284,686 | September 1, 2019 | August 31, 2025 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,278,152 | September 1, 2022 | August 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia | NIH | National Cancer Institute | 2022 to 2025 | $3,273,998 | September 1, 2022 | August 31, 2027 | ABRAMS, JULIAN | reporter.nih.gov |
| Germline and Somatic Genomic Studies in CLL | NIH | National Cancer Institute | 2021 to 2025 | $3,266,846 | July 1, 2021 | September 30, 2026 | SLAGER, SUSAN L | reporter.nih.gov |
| ARCHS4: Massive Mining of Publicly Available RNA Sequencing Data | NIH | National Cancer Institute | 2022 to 2025 | $3,258,315 | September 1, 2022 | August 31, 2027 | MA'AYAN, AVI | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | NIH | National Cancer Institute | 2021 to 2025 | $3,231,041 | August 9, 2021 | July 31, 2026 | SMALLEY, KEIRAN | reporter.nih.gov |
| Detecting and locating cancer for patients with CT-detected lung nodules | NIH | National Cancer Institute | 2022 to 2025 | $3,224,369 | September 14, 2022 | August 31, 2027 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Defining the β-catenin/CBP-catenin/CBP axis in head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $3,223,525 | December 7, 2020 | November 30, 2026 | KUKURUZINSKA, MARIA A. | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,194,826 | January 1, 2025 | December 31, 2026 | SEGAL, LEOPOLDO NICOLAS | reporter.nih.gov |
| Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,185,429 | September 21, 2021 | August 31, 2026 | AFT, REBECCA L. | reporter.nih.gov |
| Washington University Co-Clinical Imaging Research Resource | NIH | National Cancer Institute | 2021 to 2025 | $3,181,348 | March 17, 2017 | July 31, 2027 | SHOGHI, KOORESH ISAAC | reporter.nih.gov |
| Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,177,343 | July 8, 2021 | June 30, 2027 | YANG, HUSHAN | reporter.nih.gov |
| Reducing lung cancer by decoding the link between neighborhood exposure and biological responses (RECODE) | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,171,260 | May 6, 2021 | January 31, 2027 | KIM, SAGE J. | reporter.nih.gov |
| The role of BAF related complexes in regulatory T cell development and function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,171,120 | June 1, 2020 | May 31, 2025 | ZHENG, YE | reporter.nih.gov |
| A Patient-Centric Approach to Advance Functional Precision Oncology | NIH | National Cancer Institute | 2023 to 2025 | $3,167,628 | September 22, 2023 | August 31, 2028 | KEMP, CHRISTOPHER J | reporter.nih.gov |
| Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,159,973 | September 16, 2021 | August 31, 2026 | WU, JIA | reporter.nih.gov |
| Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer link | NIH | National Cancer Institute | 2021 to 2025 | $3,159,289 | September 23, 2021 | August 31, 2026 | ULRICH, CORNELIA M | reporter.nih.gov |
| Spatial functional genomics to identify regulators of the tumor microenvironment and cancer immunity | NIH | National Cancer Institute | 2023 to 2025 | $3,154,814 | September 19, 2023 | August 31, 2028 | BROWN, BRIAN D | reporter.nih.gov |
| Targeting Pediatric Cancer Vulnerabilities | NIH | National Cancer Institute | 2023 to 2025 | $3,144,539 | September 19, 2023 | August 31, 2030 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| CD4+ T cells and neoantigens in melanoma immunotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $3,143,740 | December 1, 2020 | November 30, 2026 | WANG, RONGFU | reporter.nih.gov |
| Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL) | NIH | National Cancer Institute | 2021 to 2025 | $3,143,480 | April 1, 2021 | March 31, 2027 | BROWN, JENNIFER R | reporter.nih.gov |
| Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | NIH | National Cancer Institute | 2021 to 2025 | $3,142,500 | April 1, 2021 | March 31, 2027 | TSAI, KENNETH Y | reporter.nih.gov |
| FEN1 Endonuclease as a Synthetic Lethal Target for Cancer Therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,139,888 | August 15, 2021 | July 31, 2027 | KOLODNER, RICHARD D | reporter.nih.gov |
| Oral microbiome and periodontal diseases in oral HPV infection among people living with HIV | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,134,374 | August 11, 2022 | July 31, 2027 | XIAO, CANHUA | reporter.nih.gov |
| Structural and functional studies of colibactin | NIH | National Cancer Institute | 2021 to 2025 | $3,124,458 | December 11, 2017 | February 29, 2028 | HERZON, SETH B. | reporter.nih.gov |
| Multi-scale modeling of glioma for the prediction of treatment response, treatment monitoring and treatment allocation | NIH | National Cancer Institute | 2021 to 2025 | $3,120,699 | May 1, 2021 | April 30, 2027 | GEVAERT, OLIVIER | reporter.nih.gov |
| Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation | NIH | National Cancer Institute | 2021 to 2025 | $3,120,296 | August 1, 2021 | July 31, 2027 | HAHN, THERESA E | reporter.nih.gov |
| The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data | NIH | National Cancer Institute | 2022 to 2025 | $3,120,147 | July 1, 2022 | June 30, 2027 | LIANG, HAN | reporter.nih.gov |
| Gvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation. | NIH | National Cancer Institute | 2021 to 2025 | $3,119,515 | July 1, 2020 | June 30, 2027 | VINCENT, BENJAMIN G | reporter.nih.gov |
| FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,111,179 | September 1, 2022 | August 31, 2027 | SHOGHI, KOORESH ISAAC | reporter.nih.gov |
| Center for comprehensive proteogenomic data analysis | NIH | National Cancer Institute | 2022 to 2025 | $3,109,133 | June 15, 2022 | May 31, 2027 | MANI, DENKANIKOTA R | reporter.nih.gov |
| The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,108,327 | January 1, 2021 | December 31, 2026 | ABRAMS, JULIAN | reporter.nih.gov |
| VPS72 controls Treg cell stability and adaptation to tumor microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $3,103,834 | September 19, 2023 | August 31, 2028 | MI, QING-SHENG | reporter.nih.gov |
| Leveraging canine spontaneous cancer to optimize the power of blood biopsy | NIH | National Cancer Institute | 2021 to 2025 | $3,095,555 | June 7, 2021 | May 31, 2027 | KARLSSON, ELINOR | reporter.nih.gov |
| ENCODE Mapping Center-A Comprehensive Catalog of DNase I Hypersensitive Sites | NIH | National Human Genome Research Institute | 2021 | $3,086,945 | February 1, 2021 | January 31, 2023 | STAMATOYANNOPOULOS, JOHN A | reporter.nih.gov |
| Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | NIH | National Cancer Institute | 2021 to 2025 | $3,076,366 | April 1, 2021 | March 31, 2026 | CHI, PING | reporter.nih.gov |
| A transdisciplinary approach for dissecting stem cell states in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,070,312 | September 20, 2021 | August 31, 2026 | RABADAN, RAUL | reporter.nih.gov |
| Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen | NIH | National Cancer Institute | 2021 to 2025 | $3,068,738 | September 13, 2021 | August 31, 2027 | KHAZAIE, KHASHAYARSHA | reporter.nih.gov |
| Multiethnic GWAS and TWAS to Inform Risk Prediction for Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,068,628 | May 1, 2025 | April 30, 2027 | HAIMAN, CHRISTOPHER ALAN | reporter.nih.gov |
| The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer | NIH | National Institute of Nursing Research | 2022 to 2025 | $3,064,029 | May 9, 2022 | February 28, 2027 | XIAO, CANHUA | reporter.nih.gov |
| Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,062,772 | September 22, 2021 | August 31, 2026 | MUNN, LANCE L. | reporter.nih.gov |
| Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $3,056,754 | April 1, 2021 | March 31, 2027 | DAVIS, KARA LYNN | reporter.nih.gov |
| Comprehensive and Robust Tools for Analysis of Tumor Heterogeneity and Evolution | NIH | National Cancer Institute | 2021 to 2024 | $3,055,897 | September 24, 2020 | August 31, 2025 | RAPHAEL, BENJAMIN | reporter.nih.gov |
| Building the foundations of commensal vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,047,222 | September 23, 2022 | August 31, 2027 | FISCHBACH, MICHAEL ANDREW | reporter.nih.gov |
| Integrative single cell analyses of inflammation-derived circulating hybrid cells to identify aggressive disease | NIH | National Cancer Institute | 2021 to 2025 | $3,044,035 | April 1, 2021 | March 31, 2027 | WONG, MELISSA H. | reporter.nih.gov |
| Patient-Derived Models of Prostate Cancer for Personalized Medicine | NIH | National Cancer Institute | 2021 to 2023 | $3,037,013 | August 1, 2019 | July 31, 2025 | FUTREAL, PHILLIP ANDREW | reporter.nih.gov |
| Advanced development of the Cancer Dependency Map portal (DepMap.org) | NIH | National Cancer Institute | 2021 to 2024 | $3,032,365 | September 3, 2020 | August 31, 2025 | MONTGOMERY, PHILIP | reporter.nih.gov |
| Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $3,027,488 | April 1, 2021 | June 30, 2026 | TSIRIGOS, ARISTOTELIS | reporter.nih.gov |
| Epigenetic contribution to the excess risk of MGUS in African Americans | NIH | National Cancer Institute | 2021 to 2025 | $3,018,736 | May 13, 2021 | April 30, 2027 | BROWN, ELIZABETH E | reporter.nih.gov |
| Translating buccal nanocytology for lung cancer screening into clinical practice | NIH | National Cancer Institute | 2021 to 2025 | $3,005,920 | April 15, 2018 | July 31, 2029 | BACKMAN, VADIM | reporter.nih.gov |
| The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma Patients | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,001,101 | August 11, 2022 | May 31, 2027 | VIET, CHI T. | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Epitranscriptomic mechanism of environmental stress response and tumorigenesis | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $2,993,858 | August 1, 2023 | May 31, 2031 | HE, YU-YING | reporter.nih.gov |
| Center for Critical Assessment of Genome Interpretation | NIH | National Human Genome Research Institute | 2021 to 2025 | $2,993,386 | May 13, 2015 | May 31, 2027 | BRENNER, STEVEN E | reporter.nih.gov |
| Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,974,380 | May 1, 2022 | April 30, 2027 | SISE, MEGHAN E. | reporter.nih.gov |
| Targeting of somatic hypermutation in the genome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,970,300 | June 26, 2017 | May 31, 2027 | SCHATZ, DAVID G. | reporter.nih.gov |
| Somatic Truncation Mutations of the Histone Methyltransferase MLL4 Alter Its Subcellular Localization in Bladder Cancer: Mechanistic Insight and Targeted Therapeutic Approach | NIH | National Cancer Institute | 2025 | $2,970,010 | September 16, 2025 | August 31, 2029 | SHILATIFARD, ALI | reporter.nih.gov |
| Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,969,354 | September 1, 2025 | August 31, 2027 | CHEN, YU | reporter.nih.gov |
| Systems biology of intratumoral heterogeneity in glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,962,426 | January 1, 2022 | December 31, 2026 | BALIGA, NITIN S | reporter.nih.gov |
| Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,961,810 | July 1, 2021 | June 30, 2026 | YANG, JUN J. | reporter.nih.gov |
| PD-1/PD-L1 modulation in cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,958,687 | June 21, 2010 | February 28, 2027 | PARDOLL, DREW M. | reporter.nih.gov |
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | NIH | National Cancer Institute | 2021 to 2024 | $2,958,194 | July 15, 2020 | June 30, 2025 | CAPORASO, JAMES GREGORY | reporter.nih.gov |
| Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,958,001 | September 1, 2022 | August 31, 2027 | MIYAMOTO, DAVID T. | reporter.nih.gov |
| Discovery and Characterization of Genetic Risk Loci in Sjogren's Syndrome | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,957,132 | September 7, 2020 | August 31, 2025 | LESSARD, CHRISTOPHER J | reporter.nih.gov |
| Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response | NIH | National Cancer Institute | 2021 to 2025 | $2,957,123 | June 1, 2021 | May 31, 2026 | BYERS, LAUREN AVERETT | reporter.nih.gov |
| The role of RAMS11 in colorectal cancer progression and treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $2,937,715 | August 10, 2021 | July 31, 2026 | MAHER, CHRISTOPHER A | reporter.nih.gov |
| Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,937,308 | April 1, 2021 | March 31, 2026 | GENOVESE, GIANNICOLA | reporter.nih.gov |
| Intercepting progression from pre-invasive to invasive lung adenocarcinoma | NIH | National Cancer Institute | 2021 to 2023 | $2,932,940 | September 25, 2019 | February 28, 2025 | ALTORKI, NASSER KHALED | reporter.nih.gov |
| Radiogenomic Credentialing of Head and Neck Cancer Models | NIH | National Cancer Institute | 2021 to 2025 | $2,932,365 | December 1, 2020 | November 30, 2026 | SESHADRI, MUKUND | reporter.nih.gov |
| The Evolution of Sarcoma Drug Sensitivity through Time and Space | NIH | National Cancer Institute | 2021 to 2024 | $2,930,546 | July 1, 2020 | June 30, 2025 | SORAGNI, ALICE | reporter.nih.gov |
| Backtracking Leukemia-Typical Somatic Alterations in Cord Blood at Single-cell Resolution | NIH | National Cancer Institute | 2021 to 2025 | $2,927,357 | August 1, 2021 | July 31, 2026 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,924,883 | March 1, 2022 | February 28, 2027 | DERENZO, CHRISTOPHER | reporter.nih.gov |
| Mechanisms of epitranscriptomic regulation in cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,917,446 | September 10, 2014 | August 31, 2029 | JAFFREY, SAMIE R | reporter.nih.gov |
| Modeling myelodysplasia | NIH | National Cancer Institute | 2021 to 2025 | $2,916,597 | January 1, 2021 | December 31, 2026 | GRIMES, H. LEIGHTON | reporter.nih.gov |
| Investigating the effectiveness of COVID-19 testing choices, community engagement, and culturally-embedded mHealth literacy delivery in a medically-underserved, community-based sample | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $2,906,922 | November 11, 2020 | July 31, 2023 | AL-HENDY, AYMAN | reporter.nih.gov |
| Non-invasive imaging of the anti-tumor immune response | NIH | National Cancer Institute | 2021 to 2025 | $2,904,564 | December 14, 2020 | November 30, 2026 | PISHESHA, NOVALIA | reporter.nih.gov |
| Information flow and state transitions at the system and multi-dimensional scales in leukemia progression | NIH | National Cancer Institute | 2021 to 2024 | $2,901,922 | May 1, 2020 | April 30, 2025 | ROCKNE, RUSSELL CHRISTIAN | reporter.nih.gov |
| Signaling Mechanisms in Genome Maintenance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,898,481 | April 1, 2021 | March 31, 2026 | SMOLKA, MARCUS | reporter.nih.gov |
| The Prognostic Significance and Mechanistic Determination of Chromatin Remodeling Biomarkers in Non-Functional Pancreatic Neuroendocrine Tumor | NIH | National Cancer Institute | 2021 to 2025 | $2,897,842 | July 15, 2021 | June 30, 2026 | SINGHI, AATUR DILIP | reporter.nih.gov |
| Understanding and targeting epigentic regulation of immune evasion in prostate cancer | NIH | National Cancer Institute | 2025 | $2,895,540 | August 1, 2025 | July 31, 2029 | CAI, LING | reporter.nih.gov |
| Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas. | NIH | National Cancer Institute | 2022 to 2025 | $2,894,071 | September 15, 2022 | August 31, 2027 | SAAVEDRA, HAROLD I | reporter.nih.gov |
| Function and Evolutionary Origins of the RAG Endonuclease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,890,366 | September 11, 2018 | July 31, 2028 | SCHATZ, DAVID G. | reporter.nih.gov |
| Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,885,730 | July 1, 2022 | June 30, 2027 | BERGER, MICHAEL F. | reporter.nih.gov |
| Spectrum of clinical phenotype of the BAP1-tumor predisposition syndrome (BAP1-TPDS) | NIH | National Cancer Institute | 2021 to 2025 | $2,866,346 | August 1, 2021 | July 31, 2027 | ABDEL-RAHMAN, MOHAMED H. | reporter.nih.gov |
| Identifying and targeting collateral lethal vulnerabilities in cancers | NIH | National Cancer Institute | 2023 to 2025 | $2,852,762 | April 1, 2023 | March 31, 2028 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| Development of a platform for spatial functional genomics | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,847,613 | September 1, 2020 | June 30, 2025 | BROWN, BRIAN D | reporter.nih.gov |
| Developing an Oncology Workforce for the 21st Century | NIH | National Cancer Institute | 2021 to 2024 | $2,833,124 | August 12, 2010 | July 31, 2025 | OLOPADE, OLUFUNMILAYO F. | reporter.nih.gov |
| Impact of Genetic susceptibility along the continuum from MGUS to MM | NIH | National Cancer Institute | 2022 to 2025 | $2,826,486 | May 1, 2022 | April 30, 2027 | VACHON, CELINE M | reporter.nih.gov |
| Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,815,123 | April 1, 2022 | March 31, 2027 | CORCORAN, RYAN BRUCE | reporter.nih.gov |
| Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,813,174 | July 23, 2021 | June 30, 2026 | POLITI, KATERINA ABIGAIL | reporter.nih.gov |
| Translating the tumor regulome from cell-free DNA for precision oncology | NIH | National Cancer Institute | 2022 to 2025 | $2,812,871 | September 1, 2025 | August 31, 2027 | HA, GAVIN | reporter.nih.gov |
| The role of the intestinal microbiome in cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,811,009 | August 1, 2023 | July 31, 2030 | VAN DEN BRINK, MARCEL R M | reporter.nih.gov |
| Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,809,344 | August 1, 2021 | July 31, 2026 | LITTMAN, DAN | reporter.nih.gov |
| Virus-host interactions and microbial ecology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,803,865 | May 6, 2016 | April 30, 2027 | HARSHEY, RASIKA M | reporter.nih.gov |
| Molecular and immunologic evolution of melanomas from pre-neoplastic lesions | NIH | National Cancer Institute | 2021 to 2023 | $2,803,032 | September 15, 2017 | August 31, 2025 | BASTIAN, BORIS C. | reporter.nih.gov |
| Inducing Neural Maturation in Medulloblastoma by Targeting EZH2 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,801,562 | September 15, 2022 | August 31, 2026 | SNUDERL, MATIJA | reporter.nih.gov |
| Small molecule probes of MYC stability and function intumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,799,696 | March 1, 2021 | February 28, 2027 | ABDULKADIR, SARKI A. | reporter.nih.gov |
| Discovery and characterization of clinically actionable germline mutations in DNA damage repair (DDR) pathway genes in lung cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,799,371 | June 1, 2022 | May 31, 2027 | MUKHERJEE, SEMANTI | reporter.nih.gov |
| Ecology and Evolution of Breast Carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,794,274 | September 15, 2021 | August 31, 2027 | DAMAGHI, MEHDI | reporter.nih.gov |
| A premalignant chronology of cell-state variability in basal-like breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,790,901 | January 1, 2022 | December 31, 2026 | JANES, KEVIN A | reporter.nih.gov |
| DNA evaluation of fragments for early interception (DELFI) of Lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,789,019 | July 17, 2023 | June 30, 2028 | VELCULESCU, VICTOR E. | reporter.nih.gov |
| Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans | NIH | National Cancer Institute | 2022 to 2025 | $2,785,523 | April 1, 2022 | March 31, 2027 | ELLISEN, LEIF W | reporter.nih.gov |
| DNA Adduct Detection and Repair in Mammalian Cells | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,783,115 | September 17, 2021 | June 30, 2027 | SANCAR, AZIZ | reporter.nih.gov |
| Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | NIH | National Cancer Institute | 2021 to 2025 | $2,776,685 | July 21, 2015 | June 30, 2026 | JAFFEE, ELIZABETH M. | reporter.nih.gov |
| Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,776,588 | September 16, 2021 | August 31, 2026 | YU, JIYANG | reporter.nih.gov |
| Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,771,966 | July 1, 2020 | June 30, 2025 | FENG, FELIX YI-CHUNG | reporter.nih.gov |
| A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity | NIH | National Cancer Institute | 2022 to 2025 | $2,770,577 | February 24, 2022 | January 31, 2027 | DIEFENBACH, CATHERINE SIBYL | reporter.nih.gov |
| Developmental Exposures, Stem Cell Reprogramming, and Breast Cancer Disparities | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,767,677 | January 1, 2018 | October 31, 2027 | COLACINO, JUSTIN ADAM | reporter.nih.gov |
| Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1 | NIH | National Cancer Institute | 2022 to 2025 | $2,763,196 | January 1, 2022 | December 31, 2026 | SKOK, JANE AMANDA | reporter.nih.gov |
| Cell Cycle Dynamics that Ensure Genome Maintenance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,761,043 | July 1, 2021 | June 30, 2027 | COOK, JEANETTE GOWEN | reporter.nih.gov |
| Multi-cancer early detection using cell-free DNA methylome analysis | NIH | National Cancer Institute | 2023 to 2025 | $2,757,500 | September 19, 2023 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Deciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omics | NIH | National Cancer Institute | 2021 to 2025 | $2,757,093 | April 5, 2021 | March 31, 2026 | SUVA, MARIO LUCA | reporter.nih.gov |
| Rhesus HHV-8 homologue in AIDS-related malignancies | NIH | National Cancer Institute | 2021 to 2024 | $2,752,636 | July 1, 1997 | July 31, 2025 | WONG, SCOTT W | reporter.nih.gov |
| Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,750,290 | April 1, 2020 | March 31, 2025 | BHARDWAJ, NINA | reporter.nih.gov |
| Applying Population Management Best Practices to Preventive Genomic Medicine | NIH | National Human Genome Research Institute | 2023 to 2025 | $2,742,273 | May 10, 2023 | February 29, 2028 | KNERR, SARAH | reporter.nih.gov |
| Clinical and Molecular Heterogeneity in the Myelodysplastic Syndromes | NIH | National Cancer Institute | 2021 to 2024 | $2,742,067 | April 1, 2020 | March 31, 2025 | PARK, CHRISTOPHER Y | reporter.nih.gov |
| Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety Testing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,741,939 | September 5, 2023 | August 31, 2025 | AHMED, SYED MUKHTAR | reporter.nih.gov |
| Investigating the mechanisms of driver genes associated with ancestry and aggressiveness in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,739,005 | May 10, 2021 | April 30, 2027 | CAMPBELL, JOSHUA D | reporter.nih.gov |
| Understanding druggable drivers of meningioma tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,733,596 | August 1, 2021 | July 31, 2026 | RALEIGH, DAVID R | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,717,589 | September 19, 2023 | August 31, 2025 | YEE, CASSIAN | reporter.nih.gov |
| EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | NIH | National Cancer Institute | 2022 to 2025 | $2,717,300 | July 1, 2022 | June 30, 2027 | YANG, JUN | reporter.nih.gov |
| Determinants of response to cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $2,714,641 | August 1, 2021 | July 31, 2024 | FONG, LAWRENCE | reporter.nih.gov |
| Understanding the Contribution of Colorectal Cancer Tumor Characteristics to Disparities in Colorectal Cancer Survival | NIH | National Cancer Institute | 2021 to 2025 | $2,714,017 | July 15, 2021 | June 30, 2027 | WARREN ANDERSEN, SHANEDA | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Probing the role of somatic X-chromosome alterations in shaping cancer sex differences | NIH | National Cancer Institute | 2023 to 2025 | $2,705,278 | September 20, 2023 | August 31, 2028 | VISWANATHAN, SRINIVAS RAGHAVAN | reporter.nih.gov |
| Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | NIH | National Cancer Institute | 2022 to 2025 | $2,704,822 | May 1, 2022 | April 30, 2026 | DE SMITH, ADAM | reporter.nih.gov |
| Regulation of T cell exhaustion via 3D chromatin architecture | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,704,065 | March 15, 2015 | April 30, 2030 | XUE, HAI-HUI | reporter.nih.gov |
| Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122 | NIH | National Cancer Institute | 2022 to 2025 | $2,699,777 | February 15, 2022 | December 31, 2026 | HAFLER, DAVID A. | reporter.nih.gov |
| Integration of Clinical and Molecular Biomarkers for Melanoma Survival | NIH | National Cancer Institute | 2021 to 2022 | $2,698,074 | June 1, 2017 | May 31, 2024 | BERWICK, MARIANNE | reporter.nih.gov |
| Telomeres and Telomerase in Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,688,975 | January 1, 2017 | December 31, 2024 | GREIDER, CAROL W | reporter.nih.gov |
| A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | NIH | National Cancer Institute | 2022 to 2025 | $2,688,808 | March 1, 2022 | February 28, 2027 | REINHERZ, ELLIS L | reporter.nih.gov |
| The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,686,770 | August 1, 2021 | July 31, 2026 | NEWELL, EVAN | reporter.nih.gov |
| InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $2,685,053 | September 3, 2021 | August 31, 2026 | MCKAY, JAMES DOWLING | reporter.nih.gov |
| Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia. | NIH | National Cancer Institute | 2022 to 2025 | $2,677,641 | August 1, 2022 | July 31, 2027 | STIEGLITZ, ELLIOT | reporter.nih.gov |
| Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,673,041 | August 2, 2022 | July 31, 2027 | NEAMATI, NOURI | reporter.nih.gov |
| How the 3D Architecture of the Brain Shapes Cancer Cell Fate Decisions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,670,000 | September 30, 2021 | August 31, 2026 | FILBIN, MARIELLA GRUBER | reporter.nih.gov |
| MYC-regulated RNA Binding Protein Networks and Spliced Isoforms Driving Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,668,290 | February 10, 2021 | January 31, 2027 | ANCZUKOW-CAMARDA, OLGA | reporter.nih.gov |
| Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and Behaviors | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,663,131 | May 28, 2020 | March 31, 2025 | FIGUEIREDO, JANE C. | reporter.nih.gov |
| Advancing equity in colorectal cancer genetic risk prediction through expansion of racial/ethnic minority representation | NIH | National Cancer Institute | 2021 to 2024 | $2,661,057 | July 1, 2020 | June 30, 2025 | PETERS, ULRIKE | reporter.nih.gov |
| The Molecular and Genetic Pathogenesis of LAM | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,660,652 | September 21, 2016 | February 28, 2026 | HENSKE, ELIZABETH P | reporter.nih.gov |
| An integrative omics approach to investigate gene-environment interaction in colorectal cancer risk | NIH | National Cancer Institute | 2023 to 2025 | $2,659,982 | June 1, 2023 | May 31, 2028 | PETERS, ULRIKE | reporter.nih.gov |
| In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,657,653 | September 20, 2022 | August 31, 2027 | ROSENBLUTH, JENNIFER M. | reporter.nih.gov |
| Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation | NIH | National Cancer Institute | 2022 to 2025 | $2,656,507 | September 1, 2022 | August 31, 2027 | LONDON, CHERYL A | reporter.nih.gov |
| Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,649,907 | September 1, 2022 | August 31, 2027 | ZAHAROFF, DAVID | reporter.nih.gov |
| Structural studies of viral replication and invasion | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,649,373 | July 1, 2016 | December 31, 2026 | AIHARA, HIDEKI | reporter.nih.gov |
| Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | NIH | National Cancer Institute | 2021 to 2024 | $2,647,966 | July 1, 2021 | June 30, 2026 | HITCHINS, MEGAN P | reporter.nih.gov |
| Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,644,746 | August 1, 2022 | July 31, 2027 | WEISS, WILLIAM A | reporter.nih.gov |
| Targeting Lymph Node Dependent Immune Tolerance in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,643,851 | April 1, 2021 | March 31, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,642,372 | September 1, 2022 | August 31, 2027 | YAMOAH, KOSJ | reporter.nih.gov |
| Synthetic lethalities to cell cycle disruption in glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,642,252 | May 13, 2022 | April 30, 2027 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| Overture: A Multi-Scale Data Platform for Cancer Genomics Research | NIH | National Cancer Institute | 2021 to 2025 | $2,635,118 | September 9, 2021 | August 31, 2027 | YUNG, CHRISTINA | reporter.nih.gov |
| OpenCRAVAT: Informatics Tools for High-Throughput Analysis of Cancer Mutations | NIH | National Cancer Institute | 2022 to 2025 | $2,632,235 | May 15, 2022 | April 30, 2027 | KARCHIN, RACHEL | reporter.nih.gov |
| Liquid biopsy approaches to inform neuroblastoma prognosis and disease monitoring | NIH | National Cancer Institute | 2022 to 2025 | $2,631,965 | April 11, 2022 | March 31, 2027 | APPLEBAUM, MARK ANDREW | reporter.nih.gov |
| Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival | NIH | National Cancer Institute | 2022 to 2025 | $2,628,801 | June 2, 2022 | May 31, 2027 | SONG, MINGYANG | reporter.nih.gov |
| Structurally dissecting APOBEC3's for HIV-1 restriction and beyond | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,626,543 | September 1, 2016 | August 31, 2025 | SCHIFFER, CELIA A. | reporter.nih.gov |
| Understanding the role of area-level factors, smoking, and epigenetics in lung cancer risk across populations groups | NIH | National Cancer Institute | 2022 to 2025 | $2,625,326 | July 1, 2022 | June 30, 2027 | CHENG, IONA C | reporter.nih.gov |
| Translation of a novel combination therapy approach for non-Hodgkin lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,620,855 | September 1, 2022 | August 31, 2027 | NAIK, SHRUTHI | reporter.nih.gov |
| The role of the nucleolus in human genome organization in normal and disease states | NIH | National Cancer Institute | 2021 to 2024 | $2,619,610 | September 21, 2020 | August 31, 2025 | KAUFMAN, PAUL D. | reporter.nih.gov |
| Pharmacogenomics to Catalyze Decision Support in Oncology Care | NIH | National Human Genome Research Institute | 2023 to 2025 | $2,619,474 | June 1, 2023 | March 31, 2028 | O'DONNELL, PETER HUGH | reporter.nih.gov |
| Molecular mechanisms of iAs-mediated carcinogenesis through the lens of histone H2B variants | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,613,858 | May 2, 2022 | February 28, 2027 | FONDUFE-MITTENDORF, YVONNE NSOKIKA | reporter.nih.gov |
| Canine MHC-I genotyping and tumor specific neoantigen determination | NIH | National Cancer Institute | 2021 to 2025 | $2,606,630 | May 11, 2021 | April 30, 2027 | ZHAO, SHAYING | reporter.nih.gov |
| Mechanisms of Endogenous DNA Damage Promotion | NIH | National Cancer Institute | 2021 to 2024 | $2,589,017 | July 1, 2020 | June 30, 2025 | ROSENBERG, SUSAN M | reporter.nih.gov |
| Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR) | NIH | National Cancer Institute | 2021 to 2024 | $2,581,284 | September 10, 2020 | August 31, 2025 | JARNAGIN, WILLIAM ROBERT | reporter.nih.gov |
| Dose-Dependent Effects of Hormone on the Activity of Estrogen Receptor Enhancers and Target Genes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,576,212 | September 15, 2000 | May 31, 2030 | KRAUS, WILLIAM LEE | reporter.nih.gov |
| Functional Genomics of LINE-1 Retrotransposition | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,575,492 | April 21, 2022 | January 31, 2027 | RAMOS, KENNETH S. | reporter.nih.gov |
| Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,572,103 | July 1, 2021 | June 30, 2027 | ZHOU, GANG | reporter.nih.gov |
| Site-specific Integration of Large (10-100 kb) DNA Constructs into the Mouse Genome and Human Induced Pluripotent Stem Cells Using the Cas9-Bxb1 Integrase Toolbox | NIH | National Cancer Institute | 2022 to 2025 | $2,568,438 | July 1, 2022 | June 30, 2027 | HOSUR, VISHNU | reporter.nih.gov |
| Multi-Omic Biomarkers for Neuropathic Pain Secondary to Chemotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $2,568,308 | September 30, 2020 | August 31, 2025 | ROTROFF, DANIEL | reporter.nih.gov |
| Comprehensive molecular characterization of lung cancers in five racial/ethnic groups with disparate risk | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,566,329 | February 25, 2020 | December 31, 2025 | PARK, SUNGSHIM LANI | reporter.nih.gov |
| Impact of mutational order on molecular mechanisms of oncogenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,563,938 | May 10, 2022 | February 28, 2027 | PAPAPETROU, EIRINI | reporter.nih.gov |
| Molecular Determinants of Social Factors in Prostate Cancer | NIH | National Institute on Minority Health and Health Disparities | 2021 | $2,560,268 | September 26, 2017 | July 31, 2023 | KUMAR, DEEPAK | reporter.nih.gov |
| Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,551,647 | January 1, 2022 | December 31, 2026 | MAHER, CHRISTOPHER A | reporter.nih.gov |
| Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,549,349 | July 20, 2022 | April 30, 2027 | NEUHAUSEN, SUSAN L. | reporter.nih.gov |
| Discovery, Biology and Risk of Inherited Variants in Glioma | NIH | National Cancer Institute | 2021 to 2024 | $2,549,276 | April 10, 2020 | April 30, 2026 | BONDY, MELISSA L. | reporter.nih.gov |
| Novel Technologies to Isolate and Analyze Extrachromosomal DNAs for Diagnostic Applications | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,544,007 | August 1, 2023 | July 31, 2027 | SHOURA, MASSA | reporter.nih.gov |
| Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,543,302 | February 19, 2021 | January 31, 2027 | KADARA, HUMAM | reporter.nih.gov |
| Delineating developmental programs driving tumorigenesis in triple-negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,543,272 | February 1, 2021 | January 31, 2027 | NEWMAN, AARON M | reporter.nih.gov |
| The unleashed microbiome of cancer patients as a discovery platform for rational microbiome engineering | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,542,500 | August 13, 2021 | July 31, 2026 | SCHLUTER, JONAS | reporter.nih.gov |
| Circadian Clock and Myc-dependent Regulation of Cellular Transformation | NIH | National Cancer Institute | 2022 to 2025 | $2,542,136 | January 1, 2022 | December 31, 2026 | MASRI, SELMA | reporter.nih.gov |
| Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,537,016 | June 1, 2022 | May 31, 2027 | LANDAU, DAN | reporter.nih.gov |
| CDKN2A couples lipid metabolism to ferroptosis in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,535,633 | April 1, 2021 | January 31, 2026 | NATHANSON, DAVID A. | reporter.nih.gov |
| Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC | NIH | National Cancer Institute | 2022 to 2025 | $2,528,918 | September 16, 2020 | December 31, 2026 | HALABI, SUSAN | reporter.nih.gov |
| Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,526,750 | September 13, 2022 | August 31, 2027 | GENTLES, ANDREW J. | reporter.nih.gov |
| Role of METTL3 and the m6A Epitranscriptome in cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,524,158 | December 11, 2019 | November 30, 2024 | GREGORY, RICHARD I. | reporter.nih.gov |
| Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance | NIH | National Cancer Institute | 2022 to 2025 | $2,524,055 | July 15, 2022 | June 30, 2027 | WANG, LINGHUA | reporter.nih.gov |
| Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2024 | $2,518,197 | July 1, 2020 | June 30, 2025 | DEININGER, MICHAEL W. | reporter.nih.gov |
| Resident Memory T Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,513,593 | August 19, 2020 | January 31, 2030 | MASOPUST, DAVID | reporter.nih.gov |
| NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,512,290 | September 1, 2020 | May 31, 2026 | RAMESH, VIJAYA | reporter.nih.gov |
| Finding the optimal balance of immunotherapy efficacy and toxicity. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,511,216 | June 12, 2020 | May 31, 2025 | GERBER, DAVID ERIC | reporter.nih.gov |
| Mapping the regulatory landscape of RNA binding proteins and their causal roles in tumorigenesis and patient survival | NIH | National Cancer Institute | 2021 to 2025 | $2,506,280 | February 12, 2021 | January 31, 2027 | TAVAZOIE, SAEED F | reporter.nih.gov |
| The Role of Kaiso as a predictive breast cancer biomarker in Africa and across the African Diaspora | NIH | National Cancer Institute | 2022 to 2025 | $2,504,798 | September 1, 2022 | August 31, 2027 | GARDNER, KEVIN L. | reporter.nih.gov |
| Dissecting Phenotype Switching in Early Stage Melanomas | NIH | National Cancer Institute | 2022 to 2025 | $2,502,851 | August 4, 2022 | July 31, 2027 | SCHOBER, MARKUS | reporter.nih.gov |
| Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients | NIH | National Cancer Institute | 2022 to 2025 | $2,501,120 | June 13, 2022 | May 31, 2027 | KAPILA, YVONNE L | reporter.nih.gov |
| The Genetics of Ocular Melanoma | NIH | National Cancer Institute | 2021 to 2024 | $2,499,142 | July 1, 2011 | February 28, 2026 | BOWCOCK, ANNE MARY | reporter.nih.gov |
| Dysregulation of Innate Lymphoid Immunity in Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,498,906 | September 1, 2021 | August 31, 2027 | MUNDY-BOSSE, BETHANY | reporter.nih.gov |
| Understanding the role of autophagy-regulated cell death in the escape from replicative crisis | NIH | National Cancer Institute | 2021 to 2024 | $2,497,589 | December 1, 2019 | May 31, 2025 | KARLSEDER, JAN | reporter.nih.gov |
| Radiation and dendritic cells to hepatomas to improve immunotherapy response | NIH | National Cancer Institute | 2022 to 2025 | $2,485,861 | September 1, 2022 | August 31, 2027 | PARK, SEAN S | reporter.nih.gov |
| KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,481,052 | September 30, 2020 | May 31, 2026 | MIGNOT, EMMANUEL J | reporter.nih.gov |
| Epigenetics and 3D Structure of miR-10b/HoxD Locus in the Brain and Malignant Glioma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,479,682 | September 15, 2020 | July 31, 2025 | KRICHEVSKY, ANNA M. | reporter.nih.gov |
| Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics | NIH | National Cancer Institute | 2021 to 2024 | $2,478,422 | February 3, 2020 | January 31, 2026 | BEEBE, DAVID J | reporter.nih.gov |
| Downstream effects of HPV integration on survival/metastasis in oropharyngeal cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,477,895 | July 1, 2020 | December 31, 2025 | SARTOR, MAUREEN AGNES | reporter.nih.gov |
| Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,477,583 | March 15, 2017 | June 30, 2027 | NG, KIMMIE | reporter.nih.gov |
| Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization | NIH | National Cancer Institute | 2022 to 2025 | $2,477,191 | December 3, 2021 | November 30, 2026 | HUANG, SUMING | reporter.nih.gov |
| Genome Architecture in Human Germinal Center B Cell Development, Malignancy, and Somatic Hypermutation | NIH | National Cancer Institute | 2021 to 2024 | $2,471,907 | September 15, 2020 | August 31, 2025 | SCHATZ, DAVID G. | reporter.nih.gov |
| Targeting Myeloid Metabolism to Reprogram the Tumor Microenvironment of Glioblastoma | NIH | National Cancer Institute | 2025 | $2,467,799 | August 18, 2025 | July 31, 2029 | STEGH, ALEXANDER H. | reporter.nih.gov |
| Imaging signatures of genetic mutations in glioblastoma using machine learning | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,467,136 | June 1, 2002 | November 30, 2025 | DAVATZIKOS, CHRISTOS | reporter.nih.gov |
| Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,463,397 | August 1, 2020 | April 30, 2026 | DIEHN, MAXIMILIAN | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program - Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,458,093 | August 1, 2015 | June 30, 2026 | LOCK, RICHARD B | reporter.nih.gov |
| Instability of Cancer Cell States in Tumor progression (ICCS) | NIH | National Cancer Institute | 2021 to 2025 | $2,456,986 | September 21, 2021 | August 31, 2027 | HUANG, SUI | reporter.nih.gov |
| A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,436,171 | April 1, 2021 | June 30, 2026 | FANGER, GARY | reporter.nih.gov |
| Polymerase epsilon-based mouse and derived organoid models of intestinal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,435,094 | September 15, 2022 | August 31, 2027 | CASTRILLON, DIEGO H | reporter.nih.gov |
| Mechanisms of Epigenetic Plasticity in PDAC | NIH | National Cancer Institute | 2021 to 2025 | $2,434,090 | April 1, 2021 | March 31, 2027 | YI, CHUNLING | reporter.nih.gov |
| Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmittedby the LINC Complex | NIH | National Cancer Institute | 2021 to 2024 | $2,427,404 | March 6, 2020 | February 28, 2026 | LELE, TANMAY P. | reporter.nih.gov |
| A nucleus-to-mitochondria nucleic acid-sensing pathway prevents bypass of age-associated proliferative boundaries | NIH | National Institute on Aging | 2022 to 2025 | $2,426,262 | September 30, 2022 | June 30, 2027 | KARLSEDER, JAN | reporter.nih.gov |
| Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,423,705 | April 1, 2022 | March 31, 2027 | ELLINGSON, BENJAMIN M. | reporter.nih.gov |
| Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology | NIH | National Cancer Institute | 2023 to 2025 | $2,416,050 | September 7, 2023 | August 31, 2028 | CHI, HONGBO | reporter.nih.gov |
| Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen Levels | NIH | National Cancer Institute | 2021 to 2025 | $2,414,500 | April 1, 2020 | March 31, 2030 | WITTE, JOHN S. | reporter.nih.gov |
| Metabolic Imaging of Targeted Therapies in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,412,354 | January 17, 2022 | December 31, 2026 | NATH, KAVINDRA | reporter.nih.gov |
| Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,410,423 | August 1, 2021 | July 31, 2026 | IQBAL, JAVEED | reporter.nih.gov |
| Immune Exclusion in Cancer Immunotherapy | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,407,666 | September 1, 2022 | July 31, 2027 | BAO, RIYUE | reporter.nih.gov |
| Understanding and targeting mutant splicing factors in pancreatic cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,406,506 | September 21, 2022 | August 31, 2027 | ESCOBAR HOYOS, LUISA | reporter.nih.gov |
| Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution | NIH | National Cancer Institute | 2021 to 2025 | $2,405,560 | July 1, 2025 | June 30, 2027 | CROMPTON, BRIAN | reporter.nih.gov |
| Credentialing next-generation human glioma models for precision therapeutics | NIH | National Cancer Institute | 2022 to 2025 | $2,403,397 | January 12, 2022 | December 31, 2026 | MILLER, CHRISTOPHER RYAN | reporter.nih.gov |
| Liquid biopsy of solitary pulmonary nodule with extracellular vesicles | NIH | National Cancer Institute | 2021 to 2025 | $2,402,652 | September 21, 2021 | August 31, 2026 | WAN, YUAN | reporter.nih.gov |
| The Gut Microbiome, Lifestyle, and Colorectal Neoplasia | NIH | National Cancer Institute | 2022 to 2025 | $2,397,399 | May 1, 2022 | April 30, 2027 | SONG, MINGYANG | reporter.nih.gov |
| Preventing adaptive drug resistance through Mediator kinase inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,396,222 | August 1, 2022 | July 31, 2027 | CHEN, MENGQIAN | reporter.nih.gov |
| STAG2 modulates environmental toxicant exposures and epigenomic heterogeneity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,388,852 | March 20, 2022 | December 31, 2026 | OHM, JOYCE ELLEN | reporter.nih.gov |
| Hematopoietic Regulation via GATA Switches | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,385,213 | February 1, 2006 | November 30, 2029 | BRESNICK, EMERY H. | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Histone Deacetylation Signaling in Aging and Cancer Pathways | NIH | National Cancer Institute | 2021 to 2025 | $2,374,193 | July 9, 2021 | August 31, 2026 | CHUA, KATRIN F. | reporter.nih.gov |
| Cytomegalovirus as an etiologic and clinico-pathogenic factor in childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,371,097 | June 21, 2022 | May 31, 2028 | WIEMELS, JOSEPH LEO | reporter.nih.gov |
| MELT: Modulation of PSMA Expression for Lutetium Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,363,818 | July 1, 2019 | June 30, 2026 | HOPE, THOMAS A | reporter.nih.gov |
| Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutations | NIH | National Cancer Institute | 2021 to 2025 | $2,360,075 | March 17, 2021 | May 31, 2026 | GEELEHER, PAUL | reporter.nih.gov |
| Targeting integrated metabolic and epigenetic pathways in childhood ependymomas | NIH | National Cancer Institute | 2022 to 2025 | $2,359,774 | July 5, 2022 | June 30, 2027 | VENNETI, SRIRAM | reporter.nih.gov |
| Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,358,284 | July 1, 2020 | June 30, 2026 | DIEHN, MAXIMILIAN | reporter.nih.gov |
| Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion | NIH | National Cancer Institute | 2022 to 2025 | $2,358,103 | February 1, 2022 | January 31, 2027 | VLACHOS, IOANNIS | reporter.nih.gov |
| New Therapuetics for Pancreatic Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,353,939 | May 3, 2022 | April 30, 2027 | FERNANDEZ-ZAPICO, MARTIN ERNESTO | reporter.nih.gov |
| Development of Advanced Preclinical Models for Pediatric Solid Tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,351,834 | March 5, 2020 | February 28, 2025 | SWEET-CORDERO, ERIC ALEJANDRO | reporter.nih.gov |
| Mechanisms of progression of vascular malformation to lymphangiosarcoma | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,351,725 | April 8, 2003 | June 30, 2027 | GUAN, JUN-LIN | reporter.nih.gov |
| MTSS1 in myocardial disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,347,598 | July 15, 2019 | May 31, 2029 | CAPPOLA, THOMAS P. | reporter.nih.gov |
| Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model | NIH | National Cancer Institute | 2021 to 2024 | $2,342,069 | March 1, 2020 | February 28, 2026 | FIELDS, RYAN C | reporter.nih.gov |
| Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,339,824 | April 1, 2022 | March 31, 2027 | GAO, ALLEN C. | reporter.nih.gov |
| Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,339,120 | April 15, 2021 | June 30, 2024 | ZHU, YUAN | reporter.nih.gov |
| Chromatin Dynamics and Genome Regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,335,578 | August 4, 2017 | May 31, 2027 | BANASZYNSKI, LAURA | reporter.nih.gov |
| Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition | NIH | National Cancer Institute | 2023 to 2025 | $2,330,499 | September 15, 2023 | August 31, 2028 | ALEXANDROV, LUDMIL B | reporter.nih.gov |
| Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy Response | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,329,025 | July 18, 2024 | April 30, 2028 | RAMANUJAM, NIRMALA | reporter.nih.gov |
| Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma | NIH | National Cancer Institute | 2021 to 2024 | $2,327,927 | December 13, 2019 | November 30, 2025 | RAJ, ARJUN | reporter.nih.gov |
| PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer Research | NIH | National Cancer Institute | 2021 to 2023 | $2,327,659 | September 20, 2013 | July 31, 2025 | TANGEN, CATHERINE M. | reporter.nih.gov |
| Metabolic Regulation of Glioblastoma Epitranscriptomics | NIH | National Cancer Institute | 2022 to 2025 | $2,327,158 | July 7, 2022 | June 30, 2027 | AGNIHOTRI, SAMEER | reporter.nih.gov |
| Molecular mechanisms of prostate cancer metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,326,612 | January 1, 2015 | June 30, 2027 | ABATE-SHEN, CORY | reporter.nih.gov |
| Genomics of childhood acute lymphoblastic leukemia in the Childhood Cancer and Leukemia International Consortium | NIH | National Cancer Institute | 2022 to 2025 | $2,325,747 | August 22, 2022 | July 31, 2027 | SPECTOR, LOGAN G. | reporter.nih.gov |
| Bottom-Up Assembly of Functional Salivary Gland Tissues | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,324,071 | May 1, 2021 | January 31, 2027 | JIA, XINQIAO | reporter.nih.gov |
| Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment | NIH | National Cancer Institute | 2021 to 2024 | $2,320,897 | July 1, 2020 | June 30, 2025 | MILLER-JENSEN, KATHRYN | reporter.nih.gov |
| Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition | NIH | National Cancer Institute | 2021 to 2024 | $2,320,161 | July 2, 2020 | June 30, 2025 | MEHNERT, JANICE M. | reporter.nih.gov |
| Sexual Dimorphism in Bladder Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,318,010 | August 2, 2022 | July 31, 2027 | LI, XUE SEAN | reporter.nih.gov |
| DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,315,838 | September 28, 2015 | June 30, 2025 | FISHER, WILLIAM E | reporter.nih.gov |
| Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | NIH | National Cancer Institute | 2021 to 2025 | $2,315,488 | April 1, 2015 | August 31, 2025 | SAWYERS, CHARLES L. | reporter.nih.gov |
| Genetic susceptibility to Barrett's esophagus: From GWAS to biology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,315,127 | December 21, 2021 | November 30, 2026 | BUAS, MATTHEW FRANK | reporter.nih.gov |
| Improving efficacy of radioiodine treatment of thyroid cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,314,655 | April 1, 2021 | March 31, 2026 | FAGIN, JAMES A | reporter.nih.gov |
| Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma | NIH | National Cancer Institute | 2021 to 2025 | $2,314,190 | February 1, 2019 | February 28, 2029 | GREEN, KATHLEEN JANEE | reporter.nih.gov |
| Improving risk allocation and developing novel therapies for children with T-ALL and T-LL | NIH | National Cancer Institute | 2023 to 2025 | $2,310,556 | May 4, 2015 | January 31, 2028 | TEACHEY, DAVID T. | reporter.nih.gov |
| Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,305,974 | March 1, 2022 | February 28, 2027 | FEDIRKO, VERONIKA | reporter.nih.gov |
| The role of N6-methyladenosine RNA modification in programmed and aberrant DNA mutagenesis in B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,301,592 | September 9, 2020 | November 30, 2029 | BASU, UTTIYA | reporter.nih.gov |
| Metabolism of cancer chemotherapeutics by the human gut microbiome | NIH | National Cancer Institute | 2023 to 2025 | $2,300,078 | September 1, 2023 | August 31, 2028 | TURNBAUGH, PETER JAMES | reporter.nih.gov |
| HER2-mediated delivery of cytotoxic agents in solid tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,298,246 | April 1, 2021 | March 31, 2025 | CHANDARLAPATY, SARAT | reporter.nih.gov |
| Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue Contexts | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,298,000 | September 15, 2022 | August 31, 2027 | UHLER, CAROLINE | reporter.nih.gov |
| Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,296,728 | February 1, 2022 | January 31, 2027 | LI, CHUN | reporter.nih.gov |
| Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,295,485 | January 15, 2021 | January 31, 2026 | HORMOZ, SAHAND | reporter.nih.gov |
| Interrogation of the Impact of Selection on the Evolution of Human Pancreatic Cancer Precursor Lesions | NIH | National Cancer Institute | 2022 to 2025 | $2,293,529 | September 15, 2022 | August 31, 2027 | WOOD, LAURA DELONG | reporter.nih.gov |
| Cancer Genomics: Integrative and Scalable Solutions in R/Bioconductor | NIH | National Cancer Institute | 2021 to 2023 | $2,292,828 | September 1, 2021 | August 31, 2024 | WALDRON, LEVI | reporter.nih.gov |
| Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis | NIH | National Cancer Institute | 2023 to 2025 | $2,290,302 | January 1, 2022 | December 31, 2026 | LI, BO | reporter.nih.gov |
| Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $2,289,208 | May 1, 2021 | April 30, 2027 | NIXON, DOUGLAS F | reporter.nih.gov |
| Regulation of EBV Latency by Purine Metabolism and Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,287,875 | May 19, 2021 | April 30, 2027 | TEMPERA, ITALO | reporter.nih.gov |
| Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,286,893 | June 1, 2020 | May 31, 2026 | GNJATIC, SACHA | reporter.nih.gov |
| HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,286,846 | August 1, 2023 | July 31, 2028 | GARON, EDWARD B | reporter.nih.gov |
| Towards Robust Multiplex Genome Engineering Beyond CRISPR-Cas9 | NIH | National Human Genome Research Institute | 2021 to 2025 | $2,286,025 | September 1, 2020 | May 31, 2026 | CONG, LE | reporter.nih.gov |
| Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,284,413 | July 21, 2020 | June 30, 2025 | XU, YAN | reporter.nih.gov |
| Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas | NIH | National Cancer Institute | 2021 to 2024 | $2,283,773 | December 11, 2017 | February 28, 2026 | RAO, ARVIND | reporter.nih.gov |
| Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1 | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,281,119 | September 1, 2020 | June 30, 2025 | LARGAESPADA, DAVID ANDREW | reporter.nih.gov |
| Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,280,885 | July 1, 2017 | April 30, 2028 | BRUCE, JEFFREY N | reporter.nih.gov |
| Identification and characterization of cancer cell states by novel computational and experimental technologies - Resubmission - 1 | NIH | National Cancer Institute | 2022 to 2025 | $2,279,461 | June 21, 2022 | May 31, 2027 | YANAI, ITAI | reporter.nih.gov |
| Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,273,957 | September 1, 2022 | August 31, 2027 | KNAPP, DEBORAH W | reporter.nih.gov |
| Targeting Go and Grow in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,271,628 | September 1, 2020 | June 30, 2025 | ROSENFELD, STEVEN S | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2025 | $2,270,520 | September 19, 2023 | August 31, 2028 | YEE, CASSIAN | reporter.nih.gov |
| Development of a multi-omic clinical decision platform to guide personalized therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,266,279 | February 6, 2020 | January 31, 2026 | PAREKH, SAMIR | reporter.nih.gov |
| Pathogenesis of Early Onset Colorectal Cancer: Microbiome Contributions and Mechanisms | NIH | National Cancer Institute | 2021 to 2025 | $2,266,043 | September 23, 2021 | August 31, 2026 | SEARS, CYNTHIA | reporter.nih.gov |
| Cellular plasticity gives rise to phenotypic equilibrium in small cell lung carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,265,527 | September 1, 2022 | August 31, 2027 | ABAZEED, MOHAMED E. | reporter.nih.gov |
| A platform to functionally sort and analyze tumor cells within combinatorial metastatic micorenvironments | NIH | National Cancer Institute | 2021 to 2024 | $2,264,251 | May 8, 2020 | April 30, 2025 | WOOD, DAVID KEVIN | reporter.nih.gov |
| Reverse-engineering precision liver cancer chemoprevention | NIH | National Cancer Institute | 2021 to 2023 | $2,262,334 | September 23, 2019 | August 31, 2025 | HOSHIDA, YUJIN | reporter.nih.gov |
| Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,258,753 | April 1, 2021 | March 31, 2026 | VIALE, ANDREA | reporter.nih.gov |
| Innate DC Govern TH Polarization through the Novel Regulator AIMp1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,257,260 | May 1, 2021 | April 30, 2025 | DECKER, WILLIAM KARL | reporter.nih.gov |
| Metabolic checkpoint in dendritic cell subsets and adaptive immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,256,250 | February 1, 2024 | December 31, 2028 | CHI, HONGBO | reporter.nih.gov |
| Targeting Epigenomic Regulators at the Replication Fork in PDAC | NIH | National Cancer Institute | 2021 to 2025 | $2,253,755 | April 1, 2021 | March 31, 2027 | LOMBERK, GWEN | reporter.nih.gov |
| Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,252,988 | February 12, 2021 | January 31, 2026 | WAJAPEYEE, NARENDRA | reporter.nih.gov |
| SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Health Disparity in Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,252,222 | September 11, 2023 | August 31, 2028 | KASTRATI, IRIDA | reporter.nih.gov |
| The Microbiome and Mucosal Immunity in Cervical Cancer Disparities | NIH | National Cancer Institute | 2022 to 2025 | $2,247,793 | April 25, 2022 | March 31, 2027 | BURGENER, ADAM | reporter.nih.gov |
| Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell Invasion | NIH | National Cancer Institute | 2021 to 2025 | $2,246,741 | April 1, 2021 | March 31, 2027 | VERTINO, PAULA M. | reporter.nih.gov |
| Targeting the metastasis initiating cell in undifferentiated pleomorphic sarcoma | NIH | National Cancer Institute | 2021 to 2025 | $2,239,213 | April 6, 2021 | March 31, 2027 | ALMAN, BENJAMIN AARON | reporter.nih.gov |
| Integrative Cancer Epigenomic Data Analysis Center (ICE-DAC) | NIH | National Cancer Institute | 2021 to 2025 | $2,238,963 | September 1, 2021 | August 31, 2026 | LAIRD, PETER W | reporter.nih.gov |
| 3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation | NIH | National Cancer Institute | 2021 to 2024 | $2,235,130 | July 1, 2020 | June 30, 2025 | COSTELLO, JOSEPH F | reporter.nih.gov |
| Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,232,473 | January 1, 2023 | December 31, 2027 | MARSON, ALEXANDER | reporter.nih.gov |
| PROMINENT - Stanford | NIH | National Cancer Institute | 2022 to 2025 | $2,229,065 | June 22, 2022 | May 31, 2026 | LUNDBERG, EMMA | reporter.nih.gov |
| Stem Cells and Aging | NIH | National Institute of General Medical Sciences | 2021 | $2,226,780 | July 1, 2017 | June 30, 2024 | QUESENBERRY, PETER J. | reporter.nih.gov |
| CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,225,000 | April 5, 2021 | March 31, 2027 | DOUGAN, STEPHANIE | reporter.nih.gov |
| PROSPECT-Global Consortium and Risk Factor Discovery | NIH | National Cancer Institute | 2024 to 2025 | $2,222,328 | May 1, 2024 | April 30, 2026 | CAO, YIN | reporter.nih.gov |
| Mechanisms of liver metastasis and associated resistance to immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,220,950 | March 9, 2021 | February 28, 2026 | IZAR, BENJAMIN | reporter.nih.gov |
| Air Pollution and Neighborhood Stressors as Determinants of Non-Small Cell Lung Cancer (NSCLC) Mutation Patterns and Recurrence | NIH | National Cancer Institute | 2024 to 2025 | $2,217,862 | May 10, 2024 | April 30, 2029 | ERHUNMWUNSEE, LORETTA | reporter.nih.gov |
| Bridging Disparate Structural/Functional Scales: Multiscale Modeling of Genome Organization and of Viral RNA Frameshifting | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,216,859 | September 1, 2017 | May 31, 2028 | SCHLICK, TAMAR | reporter.nih.gov |
| Computational and experimental methods for scalable identification of oncogenic non-coding regions | NIH | National Cancer Institute | 2021 to 2025 | $2,213,425 | July 1, 2018 | March 31, 2029 | KHURANA, EKTA | reporter.nih.gov |
| Multiscale analysis of metabolic inflammation as a driver of breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,213,238 | September 9, 2020 | August 31, 2025 | DENIS, GERALD V | reporter.nih.gov |
| Ubiquitination, Intestinal Homeostasis and Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,211,716 | September 1, 2022 | August 31, 2027 | MA, AVERIL I | reporter.nih.gov |
| Consequences of retrotransposition on genome integrity | NIH | National Cancer Institute | 2023 to 2025 | $2,208,749 | August 1, 2023 | July 31, 2028 | BURNS, KATHLEEN H | reporter.nih.gov |
| Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcome | NIH | National Cancer Institute | 2021 to 2025 | $2,201,529 | April 1, 2021 | March 31, 2027 | CARROLL, WILLIAM L. | reporter.nih.gov |
| Connectivity mapping identified novel combination therapy for glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,198,374 | September 1, 2025 | August 31, 2027 | SHONKA, NICOLE | reporter.nih.gov |
| TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction | NIH | National Cancer Institute | 2022 to 2025 | $2,191,917 | April 1, 2022 | March 31, 2027 | PHILIP, MARY | reporter.nih.gov |
| Chemo-mediated transcriptional reprogramming in ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,191,565 | September 23, 2022 | August 31, 2027 | ADLI, MAZHAR | reporter.nih.gov |
| Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,185,961 | April 1, 2021 | March 31, 2026 | BERGER, ALICE | reporter.nih.gov |
| Supplement to Promote Diversity, Inclusion, and Career Development of a Female Scientist | NIH | National Cancer Institute | 2021 to 2022 | $2,183,954 | December 31, 2021 | August 23, 2023 | ALEMAN GUILLEN, FERNANDO | reporter.nih.gov |
| Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies | NIH | National Cancer Institute | 2021 to 2024 | $2,183,689 | July 1, 2020 | June 30, 2026 | CERCHIETTI, LEANDRO C | reporter.nih.gov |
| Genetic dissection of oncogenic Kras signaling | NIH | National Cancer Institute | 2021 to 2025 | $2,178,492 | July 1, 2021 | June 30, 2026 | WINSLOW, MONTE MEIER | reporter.nih.gov |
| Exploiting Public Metagenomic Data to Uncover Cancer-Microbiome Relationships | NIH | National Cancer Institute | 2021 to 2025 | $2,177,785 | July 1, 2019 | August 31, 2029 | WALDRON, LEVI | reporter.nih.gov |
| Mechanisms of Dynamic Transcriptional Reprogramming in Metastasis Stem Cells | NIH | National Cancer Institute | 2022 to 2025 | $2,177,395 | March 1, 2022 | January 31, 2027 | GANESH, KARUNA | reporter.nih.gov |
| Molecular Mechanisms of APOBEC-Induced Mutagenesis in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,176,422 | July 1, 2021 | June 30, 2026 | BUISSON, REMI | reporter.nih.gov |
| Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,173,427 | September 7, 2020 | June 30, 2026 | REYES, TERESA M | reporter.nih.gov |
| Uncovering colorectal cancer etiology and biology by integrating proteomics with other omics data | NIH | National Cancer Institute | 2023 to 2025 | $2,171,240 | April 11, 2023 | March 31, 2028 | GUO, XINGYI | reporter.nih.gov |
| Optimizing prognostic and predictive algorithms using residual disease (RD) genomic biomarkers in HER2+ and TNBC | NIH | National Cancer Institute | 2021 to 2025 | $2,170,498 | June 1, 2019 | May 31, 2030 | CAREY, LISA A | reporter.nih.gov |
| New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,168,990 | June 1, 2020 | May 31, 2025 | CLEVELAND, JOHN L. | reporter.nih.gov |
| Defining the molecular basis of oncogene-induced replication stress | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,168,752 | February 1, 2021 | October 31, 2026 | HUANG, TONY TUNG | reporter.nih.gov |
| lncRNA regulation of glioblastoma progression and therapeutic resistance | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,168,484 | December 1, 2021 | November 30, 2026 | YU, JENNIFER S | reporter.nih.gov |
| Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision Medicine | NIH | National Cancer Institute | 2021 to 2023 | $2,167,508 | April 2, 2019 | March 31, 2025 | GRIFFITH, OBI L. | reporter.nih.gov |
| Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,166,917 | June 6, 2023 | May 31, 2028 | SHAH, SOHRAB P | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of TX MD Anderson Can CTR | Houston, TX | 129 | $159.8 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 112 | $155.7 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 107 | $146.6 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 104 | $136.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 109 | $131.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 76 | $125.9 million | 0 | $0 |
| Washington University | Saint Louis, MO | 73 | $110.2 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 56 | $103.9 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 56 | $103.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 73 | $99.1 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 48 | $92.8 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 47 | $87.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 40 | $83.2 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 62 | $76.1 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 71 | $72.4 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 53 | $70.1 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 55 | $67.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 74 | $64.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 36 | $63.8 million | 0 | $0 |
| Yale University | New Haven, CT | 53 | $62.3 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 59 | $61 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 66 | $60.2 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 39 | $54.1 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 32 | $52.2 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 52 | $48.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 52 | $48.1 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 35 | $47 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 44 | $46.7 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 37 | $46.6 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 49 | $45.4 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 27 | $45.3 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 33 | $43.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 31 | $41.9 million | 0 | $0 |
| University of California-Santa Cruz | Santa Cruz, CA | 9 | $38.5 million | 0 | $0 |
| Duke University | Durham, NC | 45 | $37.2 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 18 | $36.9 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 18 | $36.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 42 | $33.3 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 22 | $33 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 14 | $31.9 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 21 | $30.1 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 9 | $29.2 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 19 | $28.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 28 | $28.5 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 26 | $27.6 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 8 | $27 million | 0 | $0 |
| Ohio State University | Columbus, OH | 28 | $25.9 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 39 | $25.9 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 5 | $25.3 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 9 | $23 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 23 | $22.6 million | 0 | $0 |
| University of California at Davis | Davis, CA | 22 | $22.6 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 24 | $22.5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 24 | $21.7 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 6 | $21.7 million | 0 | $0 |
| Cold Spring Harbor Laboratory | Cold Spring Harbor, NY | 25 | $21.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 29 | $21 million | 0 | $0 |
| University of Florida | Gainesville, FL | 20 | $20.6 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 22 | $20.5 million | 0 | $0 |
| University of Washington | Seattle, WA | 21 | $20.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 15 | $20.1 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 16 | $19.7 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 17 | $19 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 22 | $18.6 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 15 | $18.3 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 15 | $17.3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 16 | $17.3 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 17 | $16.7 million | 0 | $0 |
| Rockefeller University | New York, NY | 13 | $16 million | 0 | $0 |
| Georgetown University | Washington, DC | 15 | $14.6 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 22 | $14.4 million | 0 | $0 |
| Public Health Institute | Oakland, CA | 1 | $14 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 14 | $13.8 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 10 | $13.5 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 28 | $13.3 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 7 | $12.3 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 33 | $11.4 million | 0 | $0 |
| HudsonAlpha Institute for Biotechnology | Huntsville, AL | 1 | $11.3 million | 0 | $0 |
| Salk Institute for Biological Studies | La Jolla, CA | 7 | $11.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 9 | $11.1 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 6 | $10.7 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 12 | $10.5 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 14 | $10.4 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 14 | $10.4 million | 0 | $0 |
| Cornell University | Ithaca, NY | 8 | $9.9 million | 0 | $0 |
| Battelle Pacific Northwest Laboratories | Richland, WA | 4 | $9.4 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 8 | $9.4 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 10 | $9.3 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 12 | $9.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 10 | $9.3 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 8 | $8.5 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 8 | $8.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 6 | $8.1 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 10 | $8.1 million | 0 | $0 |
| Northwestern University | Chicago, IL | 6 | $8 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 7 | $8 million | 0 | $0 |
| Princeton University | Princeton, NJ | 7 | $7.8 million | 0 | $0 |
| Mayo Clinic Arizona | Scottsdale, AZ | 7 | $6.9 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 4 | $6.8 million | 0 | $0 |
| Augusta University | Augusta, GA | 4 | $6.7 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1,712 | $941,941,889 | 0 | $0 |
| 2024 | 1,852 | $880,898,510 | 0 | $0 |
| 2023 | 1,827 | $885,764,825 | 0 | $0 |
| 2022 | 1,773 | $833,130,390 | 0 | $0 |
| 2021 | 1,682 | $777,259,043 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.